ALKERAN FOR INJECTION Rx

Select the drug indication to add to your list

ALKERAN FOR INJECTION

Leukemias, lymphomas, and other hematologic cancers
Only 4 drugs may be compared at once

Generic Name and Formulations:

Melphalan HCl 50mg/vial; pwd for IV infusion after reconstitution and dilution.

Company:

GlaxoSmithKline

Select therapeutic use:

Indications for ALKERAN FOR INJECTION:

Palliative treatment of multiple myeloma when oral therapy is not appropriate.

Adult:

Give by IV infusion over 15–20 minutes. 16mg/m2 every 2 weeks for a total of 4 doses, then at 4-week intervals. Continue treatment as hematological recovery permits. Renal insufficiency (BUN≥30mg/dL): consider reducing dose by 50%.

Children:

Not recommended.

Contraindications:

Prior resistance to melphalan.

Warnings/Precautions:

Prior irradiation or chemotherapy. Bone marrow suppression. Azotemia. Monitor platelets, hemoglobin, WBC and differential at start of therapy and prior to each course; discontinue if WBC <3,000cells/µL or platelets <100,000cells/µL. Moderate to severe renal impairment. Elderly. Pregnancy (Cat.D), nursing mothers: not recommended.

Interactions:

Radiotherapy potentiates antineoplastic effect. For IV: caution with cyclosporine, cisplatin, BCNU, nalidixic acid.

See Also:

ALKERAN

Pharmacological Class:

Alkylating agent.

Adverse Reactions:

Bone marrow suppression, GI upset, hepatic dysfunction, anemia, blood dyscrasias, secondary malignancies (eg, nonlymphocytic leukemia), rash, alopecia, pulmonary fibrosis, interstitial pneumonitis, gonadal toxicity (amenorrhea, infertility); hypersensitivity reactions, cardiac arrest (rare).

How Supplied:

Tabs—50; single-use vial—1 (w. diluent)